NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

Medicenna used their Phase 2 results and patient data to help form their “hybrid” comparator model from a base of compiled data points that were used to match with their data. We know nothing about the specific sources for those matched comparators whereas NWBO’s matched comparators are listed as coming from specific trials. Their comparator was approved AFTER NWBO’s SAP was accepted/approved. So you want NWBO to go back and make changes after they led the way forward in the first place and regulators accepted their situation as pretty unique with the crossover that they insisted upon and the trial that their influence lowered the powering on?; ). Not happening because it’s not needed!; ). Best wishes.